36th Hemophilia Symposium Hamburg 2005

Epidemiology; Hemophilia Therapy - Management of Bleedings and Inhibitors; Orthopedic Treatment in Hemophiliacs; Hemostaseologic Diagnosis; Pediatric Hemostaseology; Free Lectures

36th Hemophilia Symposium Hamburg 2005

Epidemiology; Hemophilia Therapy - Management of Bleedings and Inhibitors; Orthopedic Treatment in Hemophiliacs; Hemostaseologic Diagnosis; Pediatric Hemostaseology; Free Lectures

160,49 €*

in Vorbereitung

Falls Sie eine Lieferung außerhalb DE, AT oder CH wünschen, nutzen Sie bitte unser Kontaktformular für eine Anfrage.

About 31% of the patients with a factor VIII replacement therapy develop a factor VIII inhibitor.From these are 23% low-responder ( 5BE) [8].In the case of severe hemophilia B,about 10.5% of the patients develop inhibitory antibodies [9]. Anti-factor VIII-antibodies are also seen in 15 78% healthy people without hemophilia [7, 17, 19]. Lacroix-Desmazes et al. [10, 11] showed anti-idiotypic antibodies neutralizing the inhibitory activity of the an- factor VIII antibodies in healthy people. Well-known predisposing factors for inhibitor formation are genetic features of factor VIII,which include large deletions,nonsense mutations or intrachromosomal recombinations [5, 23].Also, ethnic groups other than Caucasians (e.g.Africans) have a higher risk of developing inhibitors.Other risk factors are presumably de- ved from the immune system. For instance, a reduction of the inhibitor was seen with lower CD4+ T helper cell counts in HIV positive hemophilic patients [3,4].The development of inhibitors is very likely to be a Th-2 mediated event where cyto- nes and their receptors,T-cell receptors and the Major Histocompatibility Complex may also play an important role. Theoretical Background The substituted factor is an unknown protein for patients with a severe he- philia. Fig. 1. The normal immunoresponse (according to BAENKLER [2]) Abbreviations: TCR T cell-receptor; APC antigen presenting cell 36 I.Wieland et al.

Epidemiology
Hemophilia Therapy - Management of Bleedings and Inhibitors
Orthopedic Treatment in Hemophiliacs
Hemostaseologic Diagnostics
Pediatric Hemostaseology
Free Lectures
Poster.
ISBN 978-3-540-36714-7
Artikelnummer 9783540367147
Medientyp Buch
Copyrightjahr 2006
Verlag Springer, Berlin
Umfang XXXIV, 319 Seiten
Abbildungen XXXIV, 319 p.
Sprache Englisch